Related Experiment Video
Updated: May 26, 2026

Peptide-based Identification of Functional Motifs and their Binding Partners
Published on: June 30, 2013
Withanone binds to mortalin and abrogates mortalin-p53 complex: computational and experimental evidence
Abhinav Grover1, Didik Priyandoko, Ran Gao
1Department of Biochemical Engineering & Biotechnology, Indian Institute of Technology Delhi, Hauz Khas, New Delhi 110016, India.
Abstract:
Mortalin binds to p53 tumor suppressor protein and sequesters it in the cytoplasm. This results in an inhibition of the transcriptional activation and control of centrosome duplication functions of p53, thus contributing to human carcinogenesis. Abrogation of mortalin-p53 interaction and reactivation of p53 function could be a valid proposition for cancer therapy. In the present study, we first investigated in silico the interaction of withanone, a withanolide with anticancer activity, with mortalin. We found that withanone could bind to mortalin in a region, earlier predicted critical for binding to p53. Cationic rhodacyanine dye, MKT-077 has also shown to bind the same region and kill cancer cells selectively. We report the molecular dynamic simulations revealing the thermodynamic and structural stability of the withanone-mortalin complexes. We also demonstrate the experimental evidence of abrogation of mortalin-p53 complex by withanone resulting in nuclear translocation and functional reactivation of p53 in human cancer cells. The present study establishes a molecular interaction basis that could be used for screening and development of anticancer drugs with low toxicity to normal cells. Accurate knowledge of the 3D structure of mortalin would further enhance the potential of such analyses to understand the molecular basis of mortalin biology and mortalin based cancer therapy.
Insights
Withanone disrupts the mortalin-p53 interaction, reactivating the p53 tumor suppressor. This finding offers a new strategy for developing targeted cancer therapies with reduced toxicity.
Area of Science:
- Molecular biology
- Biochemistry
- Cancer research
Background:
- Mortalin sequesters the p53 tumor suppressor protein in the cytoplasm, inhibiting its functions and promoting cancer.
- Reactivating p53 by disrupting the mortalin-p53 interaction is a potential cancer therapy strategy.
Purpose of the Study:
- To investigate the in silico interaction of withanone with mortalin.
- To provide experimental evidence for withanone's ability to abrogate the mortalin-p53 complex and restore p53 function in cancer cells.
Main Methods:
- In silico molecular docking and dynamic simulations of withanone-mortalin interactions.
- Experimental validation of mortalin-p53 complex disruption and p53 nuclear translocation in human cancer cells.
Main Results:
- Withanone binds to mortalin in a critical p53-binding region.
- Molecular dynamics simulations confirm the stability of the withanone-mortalin complex.
- Withanone treatment leads to the dissociation of the mortalin-p53 complex, p53 nuclear translocation, and functional reactivation.
Conclusions:
- Withanone effectively disrupts the mortalin-p53 interaction, reactivating p53 in cancer cells.
- This study establishes a molecular basis for developing mortalin-targeting anticancer drugs with potentially lower toxicity.
Related Concept Videos
The Intrinsic Apoptotic Pathway
Abnormal Proliferation
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein.
Apoptosis

